Recombinant proteins produced in insect cells

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 211-225

  Treanor, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS SIALIDASE;

ANTIBODY RESPONSE; BACULOVIRUS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS; INJECTION SITE PAIN; INSECT CELL; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVACCINATION; REVIEW; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VACCINE PRODUCTION; VIRION; VIRUS PARTICLE; VIRUS STRAIN;

HEXAPODA;

EID: 77954386670     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_11     Document Type: Review

References (37)

1. Anonymous (2005) Recommended composition of influenza virus vaccines for use in the 2005-2006 influenza season. Wkly Epidemiol Rec 80:71-75
2. Arden NH, Patriarca PA, Kendal AP. (1986) Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. Options for the control of influenza.
3. Alan R Liss, Keystone, CO Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43:1135-1142
4. Bender C, Hall H, Huang J, Klimov A, Cox N, Hay A, Gregory V, Cameron K, Lim W, Subbarao K. (1999) Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-98. Virology 254:115-123
5. Betts RF, O'Brien D, Menegus M, Falsey AR, Kouides RW, Yuen JB, Barker WH. (1993) A comparison of the protective benefit of influenza (FLU) vaccine in reducing hospitalization of patients infected with FLU A or FLU B. Clin Infect Dis 17(3):573 (A257)
6. Brett EC, Johansson BE. (2005) Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemaggluti-nin and neuraminidase vaccines in a murine model system. Virology 339:273-280
7. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemaggluti-nin. Vaccine 25(19):3871-3878
8. CDC (2005) Update: influenza activity\-United States and worldwide, 2004-05 season. MMWR 54, 631-634.
9. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML. (1999) Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17(18):2265-2274
10. Fedson DS, Dunnill P. (2007) From scarcity to abundance: pandemic vaccines and other agents for "have not" countries. J Public Health Policy 28:322-340
11. Goji NA, Nolan C, Hill H, Wolf M, Rowe T, Treanor JJ. (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietman/1203/04 (H5N1 vaccine after priming with an antigenic variant. J Infect Dis 198(5):635-641
12. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis BL, Naud P, De Carvalho NS, Rotelli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765
13. Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Clemens SAC, Dubin G. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367:1247-1255
14. Johansson BE. (1999) Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17(15-16):2073-2080
15. Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS. (2003) A nasal proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21(25-26):3706-3712
16. Katz JM, Webster RG. (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160(2):191-198
17. Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM. (2000) Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 54(4):178-187
18. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT. (2004) Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 189(3):459-461
19. Kost TA, Condreay JP, Jarvis DL. (2005) Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 32:567-575
20. Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, Reed G, Wilkinson BE, Wright PF. (1996) Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 174:838-841
21. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster J-M, Leroux-Roels G. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589
22. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New Engl J Med 355(24):2513-2522
23. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, Volvovitz F, Belshe RB, Treanor JJ. (1995) Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis 171(6):1595-1598
24. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. (2005) Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50):5751-5759
25. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA. (2007) Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21):4283-4290
26. Quan FS, Huang C, Compans RW, Kang SM. (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81(7):3514-3524
27. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13(15):1399-1402
28. Swayne DE, Perdue ML, Beck JR, Garcia M, Suarez DL. (2000) Vaccines protect chickens against H5 highly pathogenic avian influenza in the face of genetic changes in field viruses over multiple years. Vet Microbiol 74(1-2):165-172
29. Treanor J, Betts R, Powers D, Belshe R, Anderson E, Lakey D, Wright P, Wilkinson B, Smith G. (1996) Evaluation of recombinant influenza virus hemagglutinins (HAs) expressed in insect cells as influenza vaccines in humans. In: Brown LE, Hampson AW, Webster RG. (eds.) Options for the control of influenza III. Elsevier, Amsterdam, pp 677-682
30. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737
31. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. (2006a) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med 354:1343-1351
32. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MMJ. (2006b) Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 193(9):1223-1228
33. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. (2007) Safety and immunogenicity of a baculovirus-expressed hemaggluti-nin influenza vaccine: A randomized controlled trial. JAMA 297:1577-1582
34. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MMJ. (2006) Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 24(12):2176-2185
35. Wood JM. (1998) Standardization of inactivated influenza vaccine. In: Nicholson KG, Webster RG, Hay AJ (eds) Textbook of influenza. Blackwell, London, pp 333-345
36. Wood JM, Oxford JS, Dunleavy U, Newman RW, Major D, Robertson JS. (1989) Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 171:214-221
37. Yuen KY, Chan PKS, Peiris M, Tsang DNC, Que TL, Shortridge KF, Cheung PT, To WK, Ho ETF, Sung R, Cheng AFB. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351:467-471